But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
The group’s deal with Sosei will see it compete with Karuna and Cerevel.
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Deciphera, Allakos and Uniqure are all set for important data disclosures.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.